These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 1291404)

  • 1. A clinical and laboratory evaluation of the behavior of tissue polypeptide antigen in liver cirrhosis.
    Collazos J; Genollá J; Ruibal A
    Digestion; 1992; 53(3-4):157-61. PubMed ID: 1291404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical and biochemical study on tissue polypeptide antigen (TPA) in non-malignant hepatic disorders.
    Collazos J; Genollá J; Ruibal A
    Scand J Clin Lab Invest; 1993 Oct; 53(6):633-7. PubMed ID: 8266011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between serum cytokeratin 19 fragment and tissue polypeptide antigen levels in patients with non-malignant diseases.
    Kashiwabara K; Nakamura H; Kiguchi T; Matsuoka T
    Clin Chim Acta; 1998 May; 273(1):35-42. PubMed ID: 9620468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of the tumor marker carbohydrate antigen 50 in liver cirrhosis. Pathogenetic considerations.
    Collazos J; Genolla J; Ruibal A
    Clin Nucl Med; 1993 Jan; 18(1):56-9. PubMed ID: 8422722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitation of tissue polypeptide antigen (TPA) in hepatic and systemic circulation in patients with chronic liver diseases.
    Puoti C; Bellis L; Guarisco R; Costanza OM; Felici R; Spilabotti L; Paglia F; Galossi A; Dell' Unto O
    J Gastroenterol Hepatol; 2009 Dec; 24(12):1847-51. PubMed ID: 19686414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of TPS, TPA and CA 19-9 measurement in pancreatic cancer.
    Plebani M; Basso D; Del Favero G; Ferrara C; Meggiato T; Fogar P; Mangano F; Ricciardi G; Burlina A
    Oncology; 1993; 50(6):436-40. PubMed ID: 8233283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue polypeptide antigen (TPA) modifications in hepatic cirrhosis, aggressive chronic hepatitis, persistent chronic hepatitis, and in minimal pathology.
    Sabbatani S; Monti M; Fini A
    Int J Biol Markers; 1988; 3(2):127-8. PubMed ID: 3243978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of transient elastography, serum markers and clinical signs for the diagnosis of compensated cirrhosis.
    Malik R; Lai M; Sadiq A; Farnan R; Mehta S; Nasser I; Challies T; Schuppan D; Afdhal N
    J Gastroenterol Hepatol; 2010 Sep; 25(9):1562-8. PubMed ID: 20796156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue polypeptide antigen (TPA) in chronic active hepatitis and mild liver diseases.
    Collazos J; Genollà J; Ruibal A
    Int J Biol Markers; 1992; 7(4):249-52. PubMed ID: 1491182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The serum tissue polypeptide antigen in the detection of hepatocellular carcinoma in cirrhotic patients.
    Leandro G; Zizzari S; Piccoli A; Manghisi OG
    Hepatogastroenterology; 1990 Oct; 37(5):449-51. PubMed ID: 2174822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The AST/ALT ratio as an indicator of cirrhosis in patients with PBC.
    Nyblom H; Björnsson E; Simrén M; Aldenborg F; Almer S; Olsson R
    Liver Int; 2006 Sep; 26(7):840-5. PubMed ID: 16911467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue polypeptide antigen and tissue polypeptide specific antigen in primary breast cancer. Evaluation in serum and tumour tissue.
    Gion M; Mione R; Barioli P; Sartorello P; Capitanio G
    Eur J Clin Chem Clin Biochem; 1994 Oct; 32(10):779-87. PubMed ID: 7865616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and laboratory evaluation of CA 19-9 in cirrhotic patients.
    Collazos J
    Eur J Med; 1992; 1(4):215-8. PubMed ID: 1341447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue polypeptide antigen and carcinoembryonic antigen as tumor markers in lung cancer.
    Lee YC; Yang PC; Kuo SH; Luh KT
    J Formos Med Assoc; 1991 Jul; 90(7):631-6. PubMed ID: 1681012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Serum concentrations of tissue polypeptide antigen and alpha 1-fetoprotein in patients with primary liver cancer, liver metastasis and liver cirrhosis].
    Polterauer P; Legenstein E; Müller M
    Wien Klin Wochenschr; 1985 Apr; 97(9):417-20. PubMed ID: 2408389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of CA 50 in nonmalignant liver diseases: a clinical and biochemical study.
    Collazos J; Genolla J; Ruibal A
    Am J Gastroenterol; 1993 Mar; 88(3):409-12. PubMed ID: 8438849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do CA 19-9 and TPA play a minor role as compared to AFP in diagnosing primary hepatocellular carcinoma?
    Leandro G; Zizzari S; Fabris C; Basso D; Elba S; Del Favero G; Meggiato T; Angonese C; Di Mario F; Manghisi OG
    Oncology; 1989; 46(6):381-5. PubMed ID: 2479897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring lung cancer with tissue polypeptide antigen: an ancillary, profitable serum test to evaluate treatment response and posttreatment disease status.
    Buccheri G; Ferrigno D
    Lung Cancer; 1995 Oct; 13(2):155-68. PubMed ID: 8581395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection.
    Sheth SG; Flamm SL; Gordon FD; Chopra S
    Am J Gastroenterol; 1998 Jan; 93(1):44-8. PubMed ID: 9448172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the behavior of carcinoembryonic antigen in cirrhotic patients.
    Collazos J; Genollà J; Ruibal A
    Int J Biol Markers; 1992; 7(4):244-8. PubMed ID: 1491181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.